Inhibition of the interaction between the complement component Clq and immune complexes.

Area of Science:

• Biochemistry
• Immunology
• Molecular Biology

Background:

• The binding of complement component 1q (Clq) to immune complexes is a critical step in the classical complement pathway.
• Identifying inhibitors of Clq binding is important for understanding immune complex regulation and developing therapeutic strategies.

Purpose of the Study:

• To investigate the inhibitory effects of various compounds, including vitamin B6 derivatives, on Clq binding to immune complexes in vitro.
• To elucidate the mechanism by which pyridoxal-5-phosphate (P5P) inhibits Clq binding.

Main Methods:

• In vitro assessment of Clq binding inhibition using insoluble immune complexes.
• Equilibrium dialysis and difference spectroscopy to study P5P-Clq and P5P-IgG interactions.
• Analysis of complement-fixing and Clq-binding capacity of modified immune complexes.

Main Results:

• Established inhibitors like heparin and polyinosinic acid were confirmed.
• Pyridoxal-5-phosphate (P5P), a vitamin B6 active substance, demonstrated significant inhibition of Clq binding.
• P5P binds to both Clq and IgG, with a higher affinity for Clq, forming Schiff bases.
• P5P-modified immune complexes retained their complement-fixing and Clq-binding capacity, suggesting P5P targets Clq directly.
• Collagen and Fc fragments also inhibited Clq binding, but required higher concentrations and acted differently.

Conclusions:

• Pyridoxal-5-phosphate (P5P) is a potent inhibitor of Clq binding to immune complexes, likely through modification of lysyl residues on Clq.
• P5P represents a promising, low-toxicity alternative to existing Clq inhibitors for modulating immune complex activity.